XNCR Stock Analysis: Buy, Sell, or Hold?
XNCR - Xencor, Inc.
$23.34
0.35 (1.52%)
▲
5d:
+12.16%
30d:
+56.12%
90d:
+96.46%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When XNCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: XNCR is 10.6% above its trading range ($21.10). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: XNCR is 10.6% above its trading range ($21.10). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: XNCR is currently trading at $23.34, which is considered extended relative to its 30-day fair value range of $16.18 to $21.10.
Technical Outlook: Technically, XNCR is in a strong uptrend. The price is approaching resistance at $23.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: XNCR scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $29.00 (+24.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XNCR is in a strong uptrend. The price is approaching resistance at $23.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: XNCR scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $29.00 (+24.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$16.18 -
$21.10
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+10.6% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.3% below Wall St target ($29.00)
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$16.18 -
$21.10
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$19.07
Resistance Level
$23.45
Current Trend
Strong Uptrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.66
Wall Street Target
$29.00
(+24.3%)
Revenue Growth (YoY)
17.5%
Profit Margin
-155.6%
Share & Embed Analysis
Last updated: August 16, 2026 8:31 PM ET
Data refreshes hourly during market hours. Next update: 9:31 PM
Data refreshes hourly during market hours. Next update: 9:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XNCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Bassil I Dahiyat
SELL
6606 shares
2026-03-06
Celia Eckert
SELL
1767 shares
2026-03-06
John R Desjarlais
SELL
2502 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 33 SELL |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$109 | 56 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 42 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 29 SELL |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 45 HOLD |
